Cargando…

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

Deregulated activity of BCR-ABL1, a nonreceptor tyrosine kinase encoded by the fusion gene resulting from the t(9;22)(q34;q11) chromosomal translocation, is thought to be the driver event responsible for initiation and maintenance of chronic myeloid leukemia (CML). BCR-ABL1 was one of the first tyro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soverini, Simona, Mancini, Manuela, Bavaro, Luana, Cavo, Michele, Martinelli, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817796/ https://www.ncbi.nlm.nih.gov/pubmed/29455643 http://dx.doi.org/10.1186/s12943-018-0780-6

Ejemplares similares

Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
por: Bavaro, Luana, et al.
Publicado: (2019)

Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia
por: De Santis, Sara, et al.
Publicado: (2022)

Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors
por: Mancini, M., et al.
Publicado: (2019)

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
por: Soverini, Simona, et al.
Publicado: (2016)

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia
por: Mancini, Manuela, et al.
Publicado: (2017)

The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities
por: Bruno, Samantha, et al.
Publicado: (2021)

14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia
por: Mancini, Manuela, et al.
Publicado: (2015)

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
por: Mancini, Manuela, et al.
Publicado: (2022)

Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights
por: Iezza, Miriam, et al.
Publicado: (2023)

Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?
por: Soverini, Simona, et al.
Publicado: (2021)

BCR-ABL1-Associated Reduction of Beta Catenin Antagonist Chibby1 in Chronic Myeloid Leukemia
por: Leo, Elisa, et al.
Publicado: (2013)

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
por: Soverini, Simona, et al.
Publicado: (2016)

Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
por: Baccarani, Michele, et al.
Publicado: (2022)

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy
por: Luatti, Simona, et al.
Publicado: (2017)

Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
por: Stuckey, Ruth, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
por: Inzoli, Elena, et al.
Publicado: (2022)

A New Paradigm of Cardio-Hematological Monitoring in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors
por: Lopina, Nataliia, et al.
Publicado: (2022)

Systemic Mastocytosis: Molecular Landscape and Implications for Treatment
por: Monaldi, Cecilia, et al.
Publicado: (2021)

Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives
por: Russo, Domenico, et al.
Publicado: (2020)

Disrupting PTPRJ transmembrane-mediated oligomerization counteracts oncogenic receptor tyrosine kinase FLT3 ITD
por: Schwarz, Marie, et al.
Publicado: (2022)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
por: Martinelli, Giovanni, et al.
Publicado: (2009)

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
por: Martinelli, Giovanni, et al.
Publicado: (2007)

Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
por: Bruno, Samantha, et al.
Publicado: (2021)

Successful treatment of chronic myeloid leukemia with tyrosine kinase inhibitors goes beyond access to drugs
por: Conchon, Monika
Publicado: (2013)

Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
por: Mancini, Manuela, et al.
Publicado: (2022)

Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy
por: Martelli, Margherita, et al.
Publicado: (2020)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia
por: Eiring, Anna M, et al.
Publicado: (2014)

The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere length in chronic myeloid leukemia
por: Deręgowska, Anna, et al.
Publicado: (2023)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
por: Barak, Avital F., et al.
Publicado: (2011)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Laneuville, Pierre
Publicado: (2018)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
por: Fernandez, Solène, et al.
Publicado: (2019)

Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
por: Langabeer, Stephen E., et al.
Publicado: (2020)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d4208765fhemsnecottufhsqcg